Oncological and functional outcomes after testis-sparing surgery in patients with germ cell tumors: a systematic review of 285 cases

Josias Bastian Grogg1 · Zeynep Hafza Dursun1 · Joerg Beyer2 · Daniel Eberli1 · Cedric Poyet1 · Thomas Hermanns1 · Christian Daniel Fankhauser1,3

Received: 28 February 2022 / Accepted: 7 May 2022 / Published online: 12 July 2022
© The Author(s) 2022

Abstract

Introduction and objectives In several urogenital cancers, organ-preserving surgery represents the preferred treatment approach, but in patients with testicular germ cell tumors (tGCTs), radical orchiectomy represents the standard of care. This study aimed to summarize published case series assessing oncological and functional outcomes after testis-sparing surgery (TSS) in patients with tGCTs.

Materials and methods A systematic literature review and individual patient data meta-analysis were conducted of published cases with tGCT treated with TSS.

Results Of 2,333 reports, we included 32 reports providing data on 285 patients, including 306 testicles treated with TSS. Adjacent germ cell neoplasia in situ (GCNIS) was described in 43%. Hypogonadism and infertility after TSS were diagnosed in 27% and 18%. In patients undergoing adjuvant testicular radiotherapy, hypogonadism was diagnosed in 40%. Patients treated with adjuvant testicular radiotherapy after TSS exhibited a significantly lower incidence of local recurrence (2% vs. 50%, \( p < 0.001 \)). Distant metastases after TSS were observed in 2%.

Conclusion The current data questions the benefits of TSS in tGCT patients. If at all, TSS should only be offered to well-informed patients with a singular testicle, excellent compliance, a singular tumor less than 2 cm located at the lower pole of the testicle, and normal preoperative endocrine function. Unless patients plan to father a child within a short time frame, adjuvant testicular radiotherapy should be recommended after TSS. Radical orchietomy remains the standard of care, but future studies may support the use of TSS in selected men.

Keywords Urology · Testis cancer · Testis-sparing surgery · Systematic review

Abbreviations

TSS Testis-sparing surgery
tGCT Testicular germ cell tumors
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-analysis
IQR Interquartile range
SD Standard deviation

GCNIS Germ cell neoplasia in situ
AFP Alpha-1 fetoprotein
bHCG Beta human chorionic gonadotropin
LDH Lactate dehydrogenase
uTSS-s Unilateral TSS in singular testis
uTSS-bi Unilateral TSS in bilateral tumors
biTSS-bi Bilateral TSS in bilateral tumors
uTSS-u Unilateral TSS in unilateral tumor
RT Radiotherapy
Gy Gray
BEP Bleomycin, etoposide and cisplatin
EP Etoposide–cisplatin
RPLND Retroperitoneal lymph node dissection
RPLN Retroperitoneal lymph nodes
LN Lymph nodes

Josias Bastian Grogg and Zeynep Hafza Dursun contributed equally.

*Christian Daniel Fankhauser
cdfankhauser@gmail.com

1 Department of Urology, University of Zurich, Zurich, Switzerland
2 Department of Oncology, Inselspital Bern, University of Bern, Bern, Switzerland
3 Department of Urology, Cantonal Hospital of Lucerne, Lucerne, Switzerland
Introduction

In several urogenital cancers, organ-preserving surgery represents the preferred treatment approach. In men with a testicular germ cell tumors (tGCT), radical orchiectomy is the standard of care. Testis-sparing surgery (TSS) potentially reduces the risk of hypogonadism, testosterone supplementation and infertility but is only a valid treatment option in men with benign or interstitial cell tumors and the risks and benefits of TSS in men with tGCT is unknown. This systematic review and meta-analysis aimed to summarize the published literature of TSS in patients with tGCT.

Materials and methods

This review was performed according to the Preferred Reporting Items for Systematic Reviews (PRISMA) statement [1, 2]. A literature search of the most important medical electronic databases was conducted to discover relevant articles published until April 25, 2020. Detailed information regarding the data acquisition and data extraction process, our statistical analysis as well as the literature search strategy, are provided in the supplementary file 1.

Results

Patient characteristics

Of the 2333 initially identified studies, 384 articles were eligible for full-text review after title and abstract screening. Finally, 32 studies were included, providing data on 285 patients, including 306 testicles treated with TSS (Suppl. Fig. 1).

Overall, the mean age at diagnosis was 31 years (± 5 SD). The median tumor size was 15 mm (IQR: 13–19; Suppl. Table 1). For 277 of 285 (97%) patients, information regarding the histologic subtype of tGCT was provided, of which 171 of 277 (62%) were diagnosed with a pure seminoma, 88 of 277 (32%) with a mixed tGCT, and 18 of 277 (7%) with a pure teratoma. Adjacent germ cell neoplasia in situ (GCNIS) was described in 120 of 277 (43%) specimens. Out of 42 (15%) patients with information on surgical margins, 31 (74%) had negative surgical margins, whereas 11 (26%) cases had positive surgical margins. Data on serum tumor markers were available in 27 of 285 (10%) patients. Out of 27 patients, elevated serum levels of alpha-fetoprotein, beta-human chorionic gonadotropin and lactate dehydrogenase were observed in 4 (15%), 2 (7%), and 1 (5%), respectively.

Clinical scenarios

Four clinical scenarios were defined (Fig. 1). In 119 of 285 (42%) patients, TSS was performed in a singular testis (uTSS-s) due to agenesis, trauma, or orchiectomy more than 24 months before TSS of the contralateral testis. In 51 of 285 (18%) patients, TSS was performed in 1 testicle, whereas the contralateral tumor was treated with orchiectomy (uTSS-bi). In 21 of 285 (7%) cases, synchronous bilateral tumors were treated with bilateral TSS (biTSS-bi). In 14 of 285 (5%) patients, unilateral TSS was used in those with a healthy contralateral testis (uTSS-u). In 80 of 285 (28%) patients, information about the clinical scenario was not clearly described.

Adjuvant therapy

Adjuvant treatment after TSS was described in 132 of 285 (46%) patients. Adjuvant radiotherapy (RT) at doses of 16 to 20 Gray to the testicles was given in 111 patients. Five patients received radiation to the paraaortic lymph nodes. Adjuvant chemotherapy was used in 26 patients; 11 patients received 2 to 3 cycles of bleomycin, etoposide, and cisplatin (BEP). Four patients received two cycles of carboplatin, and one received four cycles of etoposide–cisplatin (EP). In 9 of 132 (7%) patients, adjuvant retroperitoneal lymph node dissection (RPLND) was performed. Another 12 patients were treated with multimodal adjuvant treatments, including radio/chemotherapy and RPLND (two cases), radiotherapy and chemotherapy (two cases), and radiotherapy and RPLND (three cases).
Oncological outcomes

Local recurrence

Data on local recurrence during follow-up were provided for 270 of 285 (95%) patients. While 236 of 270 (87%) of the patients undergoing TSS exhibited no recurrence after a median follow-up of 38 months (IQR 18–57), 34 (13%) developed local recurrence after a median of 12 months (IQR 8–29; Table 1). The histologies of 34 patients with local recurrence included pure seminoma in 13 (38%), mixed GCT in 6 (18%), pure teratoma in 1 (3%), and was not specified in 14 (41%) patients. Stratified by clinical scenarios, 13 of 119 (11%) had local recurrence after uTSS-s, 1 of 14 (7%) after uTSS-u, 3 of 51 (6%) after uTSS-bi, and 1 of 21 (5%) after biTSS-bi (5%).

Treatment and outcome after local recurrence

Local recurrence was treated with salvage radical orchiectomy in 30 of 34 (88%), of which all patients remained free of disease after a median of 47 months (IQR 36–80). A repeated TSS was performed in two patients without adjuvant therapy for at least 54 and 65 months Bojanic et al. [5]. In the third patient with repeated TSS, a classical seminoma and adjacent GCNIS were diagnosed and adjuvant testicular radiotherapy of 18 Gray was provided after repeated TSS, and the patient remained free of disease Steiner et al. [15]. One patient (3%) with local recurrence did not receive additional treatment due to poor compliance and consequently developed distant metastasis and died of the disease 24 months after initial diagnosis.

Risk factors for local recurrence

The mean age at diagnosis was 28 years (±6 SD) for patients with local recurrence and 31 years (±6 SD) for patients without local recurrence (p = 0.827). The mean tumor sizes were 14 mm (±5 SD) and 14 mm (±7 SD) in patients with and without local recurrence, respectively (p = 0.945). The analysis regarding the correlation between the presence of GCNIS and local recurrence was performed based on limited individual patient data describing the GCNIS status (70 of 270 patients were available for analysis). In those patients, local recurrence was observed in 6 of 39 (16%) patients with GCNIS versus 7 of 31 (23%) patients without GCNIS (p = 0.541).

Adjuvant treatment to prevent local recurrence

Individual patient data regarding adjuvant testicular radiotherapy and local recurrence were available in 63 of 270 (23%) patients. Patients treated with adjuvant testicular radiotherapy compared to no adjuvant therapy after TSS showed a significantly lower risk of local recurrence (1 of 43 (2%) vs. 10 of 20 (50%), p < 0.001). Individual patient data to study the influence of adjuvant chemotherapy on the risk of local recurrence were available for 47 of 270 (17%) patients. No significant difference regarding local recurrence was observed in patients with or without adjuvant chemotherapy (5 of 17 (29%) vs. 6 of 30 (20%), p = 0.493).

Distant recurrence

Distant recurrence after TSS was observed in 16 of 285 (2%) patients after a median of 19 months (IQR 9–38; Table 1). The histological diagnosis for 16 patients with distant recurrence included seminoma in 2 (13%), mixed GCt in 3 (19%) and pure teratoma in 1 (6%). No information on histology was provided in 10 of 16 (63%) cases. In 8 of 16 (50%) patients, metastases were detected in the retroperitoneal lymph nodes (RPLNs). Other locations of metastatic disease in 16 patients included 1 in the chest (6%), 1 in the brain (6%), 1 in the pelvic lymph nodes (LNs) (6%), and 1 in the mediastinal LNs (6%). In 8 of 16 (50%) cases, the exact location of metastatic recurrence was not described (Suppl. Figure 2). After the diagnosis of distant recurrence in these 16 patients, 6 (38%) were treated with chemotherapy (5 patients with 2 to 4 cycles of BEP, 1 with 4 cycles of EP), 2 (13%) received an RPLND, and 1 (6%) patient received radiotherapy to the RPLN and pelvic LN. In 15 of 16 (94%) cases, there was no evidence of disease after systemic treatment during a median follow-up of 52 months (IQR 27–88). One patient with poor compliance developed local and metastatic recurrence and died of the disease 24 months after TSS.

Functional outcome

Data on functional outcomes were mentioned in 21 studies, and 94 patients were available for individual patient analyses (Table 2). In 37 of 94 (39%) patients, information on gonadal function after TSS was provided. Out of these 37 cases, normogonadism was described in 15 (41%), hypergonadotropic normogonadism in 12 (32%), and hypogonadism in 10 (27%). In patients undergoing adjuvant testicular radiotherapy and available data on functional outcomes, hypogonadism was diagnosed in 8 of 20 (40%) patients. In a subgroup analysis including only patients with TSS in a singular testicle, excluding the subgroup of 8 patients with unilateral TSS with a healthy contralateral testis, hypogonadism was described in 9 of 33 (27%) after TSS and in 7 of 16 (44%) after adjuvant testicular RT.

Information on fertility after TSS was provided in 63 cases out of 94 (67%), and 33 of the 63 (52%) patients were able to father a child after TSS or exhibited preserved...
| Author                  | N° of patients | Age | Clinical scenario | Local recurrence free survival (months) | Histology of primary tumour | Size (mm) | GCNIS in TSS testis | Adjuvant treatment after TSS | Positive surgical margin of TSS | Elevated tumour markers at recurrence | Treatment of local recurrence | Response after treatment of local recurrence |
|------------------------|----------------|-----|-------------------|----------------------------------------|----------------------------|-----------|--------------------|-------------------------------|---------------------------------|----------------------------------|-----------------------------|-----------------------------------|
| Arda et al. [3]        | 1              | 28  | uTSS-s            | 24                                     | Mixed GCT                 | 15        | 0                  | 1/1 Chemo (BEP 2 cycles)      | NR                              | 1/1 (AFP, B-HCG)                | RO                          | CR                                |
| Bojanic et al. [4]     | 1              | 30  | uTSS-u            | 39                                     | Seminoma                  | 12        | NR                 | NR                            | 0/1                             | 1/1                             | NR                          | RO                                |
| Bojanic et al. [5]     | 1              | 23  | uTSS-s            | 31                                     | Mixed GCT                 | 20        | 1/1                | 1/1 Chemo (NR)                | NR                              | 1/1                             | NR                          | RO                                |
| Bojanic et al. [5]     | 1              | 20  | uTSS-s            | 60                                     | Seminoma                  | 12        | 1/1                | 1/1 None                      | NR                              | 1/1                             | NR                          | RO                                |
| Bojanic et al. [5]     | 1              | 28  | uTSS-s            | 8                                      | Mixed GCT                 | 8         | 0                  | 1/1 None                      | NR                              | 1/1                             | NR                          | TSS                                |
| Bojanic et al. [5]     | 1              | 30  | uTSS-bi           | 13                                     | Seminoma                  | 8         | 1/1                | 1/1 Chemo (NR)                | NR                              | 1/1                             | NR                          | RO                                |
| Bojanic et al. [5]     | 1              | 16  | uTSS-s            | 12                                     | Seminoma                  | 9         | 0                  | 1/1 None                      | NR                              | 1/1                             | NR                          | TSS                                |
| Bojanic et al. [5]     | 1              | 35  | uTSS-s            | 13                                     | Seminoma                  | 20        | 1/1                | 1/1 None                      | NR                              | 1/1                             | NR                          | RO                                |
| Bojanic et al. [5]     | 1              | 24  | uTSS-s            | 4                                      | Seminoma                  | 14        | 1/1                | 1/1 None                      | NR                              | 1/1                             | NR                          | RO                                |
| Ferretti et al. [6]    | 1              | 39  | uTSS-bi           | 6                                      | Seminoma                  | 20        | 0                  | NR                            | 0/1                             | NR                              | NR                          | RO                                |
| Forbes et al. [7]      | 1              | 23  | uTSS-s            | 48                                     | Mixed GCT                 | 7         | 0                  | 1/1 Chemo (EP 4 cycles)       | 0/1                             | 1/1                             | 1/1 (LDH)                     | RO                                |
| Heidenreich et al. [8] | 1              | NR  | uTSS-bi           | 9                                      | Seminoma                  | 19        | 0                  | None                         | NR                              | NR                              | NR                          | RO                                |
| Heidenreich et al. [9] | 4              | NR  | NR                | 3, 6, 12, 165                         | NR                        | 15\a     | 3/4                | 1/4 RT (20Gy), 3/4 none       | 1/4                             | NR                              | 3 CR / 1 DOD                 |                     |
| Keske et al. [10]      | 1              | NR  | uTSS-s            | NR                                     | Seminoma                  | 12        | 1/1                | 1/1 Chemo (NR) and RT (NR)    | NR                              | 1/1                             | 0/1                         | RO                                |
| Kizilay et al. [11]    | 2              | NR  | NR                | 22, 28                                 | Seminoma                  | 11\a     | NR                 | NR                            | 2/2                             | 1/2                             | 1/2                         | RO                                |
| Lawrents-chuk et al. [12]| 2          | NR  | uTSS-s            | 8, 4                                    | Seminoma                  | 15\a     | 2/2                | 1/2 RT (NR) 1/2 RPLND         | 0/2                             | 1/2                             | 1/2                         | RO                                |
| Author          | Nr. of patients | Age | Clinical scenario | Local recurrence free survival (months) | Histology of primary tumour | Size (mm) | GCNIS in TSS testis | Adjuvant treatment after TSS | Positive surgical margin of TSS | Elevated tumour markers at recurrence | Treatment of local recurrence | Treatment of distant recurrence | Response of local recurrence |
|-----------------|-----------------|-----|-------------------|----------------------------------------|-----------------------------|-----------|---------------------|-----------------------------|---------------------------------|----------------------------------|-----------------------------|-----------------------------|-----------------------------|
| Nason et al.    | 10              | NR  | NR                | 3                                      | NR                          | 14.1^a    | NR                  | 10/10 None                   | 0/10                            | 1/10                             | RO                          | CR                          |                             |
| Sener et al.    | 1               | 23  | biTSS-bi          | 9                                      | 1                           | 8         | 0                   | 1/1 None                     | 0/1                             | NR                              | RO                          | CR                          |                             |
| Steiner et al.  | 1               | NR  | uTSS-s            | 10                                     | Teratoma                    | 17.1^a    | 1/1                 | 1/1 None                     | 0/1                             | NR                              | TSS                         | CR                          |                             |
| Xiao et al.     | 1               | 19  | uTSS-s            | 12                                     | Mixed GCT                   | 22        | 0                   | 1/1 None                     | 0/1                             | 0/1                             | RO                          | CR                          |                             |
| Forbes et al.   | 1               | 23  | uTSS-s            | 52                                     | RP                          | Mixed GCT | 7                   | 0/1                          | 1/1 Chemo (EP: 4 cycles)      | 0/1                             | Chemo (EP: 4 cycles)          | CR                          |                             |
| Heidenreich et al. | 3             | NR  | Unknown           | 6, 12, 24                             | RP, Lung, Mediastinum, Brain | NR       | 15^a                | NR                          | NR                             | NR                              | 2/3 Chemo (BEP: 3 cycles)     | 2 CR, 1 DOD                  |                             |
| Lawrentschuk et al. | 1            | NR  | uTSS-s            | 4                                      | Micrometastatic disease of unknown origin | Seminoma | 15^a                | 1/1                          | 1/1 RT (NR)                    | 1/1                             | 1/1 Chemo (BEP: 3 cycles)     | CR                          |                             |
| Lawrentschuk et al. | 1            | NR  | uTSS-bi           | 4                                      | RP                          | Teratoma | 11                  | 0/1                          | None                           | 0/1                             | 1/1 Surgery (RPLND)           | CR                          |                             |
| Morales-Barrera et al. | 1         | 32  | uTSS-s            | 13                                     | RP, Pelvic LN                | Seminoma | 7                   | 1/1                          | 1/1 None                        | 0/1                             | RT (NR)                      | CR                          |                             |
| Nason et al.    | 7               | NR  | Unknown           | LN of unknown location                 | NR                          | 14.1^a    | NR                  | 0/7 None                     | 0/7                             | NR                              | NR                          | 7 CR                        |                             |
fertility in a sperm analysis. In 11 of the 63 (18%) cases, new azoospermia or the inability to father a child was described, whereas infertility was preexisting in 19 of 63 (30%) patients.

**Discussion**

In several urogenital cancers, organ-preserving surgery represents a potential or even the preferred treatment approach. For example, in patients with kidney cancer, partial nephrectomy in singular kidneys is a surgical approach which may avoid dialysis. Similarly, in penile cancer, partial penectomy allows preservation of functional and cosmetic favorable results. In contrast, patients with testis or bladder cancer often have a multifocal disease. Further, a complete loss of testicular function has less profound impact on a patient’s daily life compared to for example the loss of renal function. Testis cancer patients will always have the option of preoperative sperm preservation or intraoperative Onco-Testicular Sperm Extraction (ONCO-TESE) as well as testosterone replacement.

In patients with testicular tumors, TSS is currently only accepted as a treatment option in patients with interstitial cell tumors or suspected benign histologies, whereas high inguinal orchiectomy represents the standard of care in patients with tGCT [13, 28, 29]. This systematic review provides further data to discuss the risks and benefits of TSS in patients with tGCT and extends previous systematic reviews in two ways [30–32]. First, we only included tGCT patients to assess the oncological and functional outcomes in this specific group of patients, while previous publications included non-germ cell histologies. Second, pre-processed data of case series were extracted on individual patient level whenever possible, allowing more detailed data analysis and the comparison of different risk and treatment groups.

The provided data support clinicians and patients in balancing oncological risks versus the functional benefits of TSS in selected tGCT patients. The oncological risks of TSS regarding the local and distant recurrence merits further discussion. Previous pathological studies have evaluated orchiectomy specimens and described multifocality in 20% to 30% [33] and adjacent GCNIS in 72% to 90% of patients [9, 34]. Given the risk of 50% for a patient with GCNIS to develop tGCT within 5 years, [35] the risk of local recurrence of at least 25% should be expected after TSS. In this review, we observed a local recurrence risk of only 13% but this lower-than-expected risk could be because of the limited follow-up of the published series and publication bias.

In this analysis, we could not identify any clinical or histopathological risk factors for local recurrence. However, it seems that adjuvant testicular radiotherapy significantly decreases the risk of local recurrence. Therefore, we suggest
### Table 2 Functional outcome for patients after TSS for testicular GCTs

| Author (year) | Nr. of patients | Clinical scenario | Age (mean or median) | Follow up time (mean or median months) | Hormonal status after TSS | Androgen substitution needed | Achieved conception | Infertility | Semen analysis after TSS | Symptoms of hypogonadism present | Time of ischemia (min) | Clamping Adjuvant treatment |
|---------------|-----------------|------------------|----------------------|----------------------------------------|--------------------------|----------------------------|-------------------------|--------------|--------------------------|-------------------------------|--------------------------|-------------------------------|
| Benelli et al. [19] | 1 | uTSS-bi | 25 | 30 | Normogonadism | 0/1 | NR | NR | NR | NR | NR | 16 | NR | none |
| Bojanic et al. [4] | 4 | uTSS-u | 33 | 60 | NR | NR | NR | 4/4 preexisting | NR | NR | NR | NR | NR | NR |
| Bojanic et al. [5] | 23 | 15 pat: uTSS-s 8 pat: uTSS-bi | 28 | 48 | NR | NR | 4 pat | 2/23: preexisting 2/23 pat: new | 4/23 Azoospermia | NR | NR | NR | NR | NR |
| De Stefani et al. [20] | 1 | uTSS-u | 31 | 35 | Normogonadism | 0/1 | NR | NR | NR | 0/1 | 18 | 1/1 | none |
| Demir et al. [21] | 1 | uTSS-bi | 32 | 30 | hypergonadotropic Normogonadism (FSH+, LH+) | 0/1 | NR | 1/1 preexisting | 1/1 Azoospermia | 0/1 | NR | 1/1 | RT (4680 cGy) |
| Ferretti et al. [6] | 17 | uTSS-bi | 32 | 28 | NR | NR | NR | 8/17: new (unable to father child) | NR | NR | NR | NR | NR | 5 pat: chemo (2 pat CAR, 3 pat BEP), 8 pat: RT (16–20 Gy) |
| Forbes t al. [7] | 1 | uTSS-s | 23 | 60 | preexisting Hypogonadism | l/l (after TSS) | NR | 1/1 Preexisting | NR | NR | NR | NR | NR | Chemo (EP: 4 cycles) |
| Heidenreich et al. [22] | 5 | 4 pat: uTSS-s 1 pat: uTSS-bi | 45 | 4 | 4 pat: hypergonadotropic Normogonadism (FSH+, LH=), 1 pat: Normogonadism | 0/5 | NR | NR | 4/5 Azoospermia | NR | NR | NR | 4 pat: RT (20 Gy) 1 pat: chemo (BEP: 2 cycles) |
| Author          | Nr. of patients | Clinical scenario | Age (mean or median) | Follow up time (mean or median months) | Hormonal status after TSS | Androgen substitution needed | Achieved conception | Infertility | Semen analysis after TSS | Symptoms of hypogonadism present | Follow up time (mean or median months) | Time of ischemia (min) | Clamping | Adjuvant treatment |
|-----------------|-----------------|-------------------|----------------------|----------------------------------------|---------------------------|-----------------------------|----------------------|-------------|------------------------|---------------------------------|----------------------------------------|---------------------|-----------|----------------------|
| Heidenreich et al. [8] | 11              | 3 pat: uTSS-s 8 pat: uTSS-bi | 50                   | 7 pat: hypergonadotropic Normogonadism (FSH +, LH =), 4 pat: Normogonadism | 0/11                       | NR                           | NR                   | NR          | NR                     | NR                              | 11/11                                 | 4 pat: chemo (3/3: BEP; each 2 cycles, 1/4: PVB; 3 cycles) | 7 pat: RT (20 Gy) | 1 pat: none |
| Heidenreich et al. [9] | 73              | 56 pat: uTSS-s 17 pat: biTSS-bi | 32                   | 91                       | NR                           | 11/73                       | NR                   | 5/10: unable to father child | NR                     | 7/73                                 | NR                                 | 73/73                                 | 46 pat: RT (18–20 Gy) |          |                      |
| Hughes [23]       | 1               | uTSS-s            | 20                   | 93                       | NR                           | NR                           | NR                   | NR          | 1/1 new                | 1/1 Azoospermia                 | 0/1                                  | 35                                | 1/1                   | none                  |
| Kazem et al. [24] | 2               | 1 pat: uTSS-s 1 pat: uTSS-bi | 40                   | 36                       | NR                           | 0/2                         | NR                   | NR          | NR                     | 2/2 Azoospermia                 | 0/2                                  | NR                                | NR                   | 2 pat: RT (1/2: 20 Gy, 1/2: 19.8 Gy) |
| Keske et al. [10] | 3               | uTSS-s            | 30                   | 47.2                     | NR                           | NR                           | NR                   | NR          | NR                     | 3/3                             | NR                                     | NR                                 | NR                   | 1 pat: chemo (NR), RT (NR) |
| Kirkali et al. [25] | 1               | uTSS-s            | 34                   | 50                       | Normogonadism with low Testosterone | 0/1                         | NR                   | 1/1 preexisting          | 1/1 Azoospermia                 | NR                                     | NR                                 | NR                   | 1/1 RT (2560 cGy) |
| Lagabrielle et al. [26] | 2           | NR                | 36                   | 20.3                     | NR                           | NR                           | NR                   | NR          | 2/2 preexisting        | NR                              | NR                                     | NR                                 | NR                   | RT (NR)               |
| Leonhartsberger [27] | 7             | 6 pat: uTSS-bi 1 pat: biTSS-bi | 39                   | 52.2                     | 2 pat: Hypogonadism new       | 0/7                         | NR                   | NR          | NR                     | NR                              | 0/7                                  | NR                                 | NR                   |                      |
| Morales-Barrera [17] | 2               | uTSS-s            | 28                   | 31.5                     | NR                           | NR                           | NR                   | 2/2 preexisting          | 2/2 Azoospermia                 | NR                                     | NR                                 | NR                   | 1 pat: RT (NR)          |
| Sener et al. [14]  | 1               | biTSS-bi          | 26                   | 18                       | NR                           | NR                           | NR                   | 1/1 preexisting          | NR                     | NR                                     | NR                                 | NR                   | NR                   |
that adjuvant testicular radiotherapy should be discussed after TSS in patients with testicular GCT unless conception is planned within a few months. In patients planning to father a child in the future, cryopreservation or ONCOTESE rather than a delay of adjuvant radiotherapy should be considered [36].

Further, as in any man with unilateral testis cancer, we suggest a testicular ultrasound follow-up after TSS for several years. In the case of a local recurrence, the published literature suggests that salvage treatment (redo TSS or orchiectomy) was successful, if early enough, to prevent metastatic disease in most patients. Furthermore, our results reveal a low distant recurrence rate of only 2% compared to the described systemic relapse rates of 15% to 25% for stage I GCTs treated with radical orchiectomy [37, 38]. This outcome might be because of a selection bias and the corresponding smaller median tumor size in this TSS cohort compared to orchiectomy cohorts.

Critics of adjuvant testicular radiotherapy argue that radiation eradicates testosterone production during long-term follow-up. In this review, 73% of men showed sufficient testosterone production of the remaining testicular tissue, and in even 60% of men after adjuvant testicular RT. However, the assessment of functional endpoints based on published case data is limited due to heterogeneous or missing descriptions regarding the pre- and post-therapeutic gonadal function. Nevertheless, our results are in line with previous data suggesting that normal testosterone levels can be observed in 70% to 100% after 2 to 3 years of follow-up [39] and in 57% after 5 years [40].

**Limitations**

Due to the lack of correlated individual patient data in some of the analyzed case series and heterogenic reporting, the presented results have a high risk of bias and should be regarded as hypothesis-generating. Specifically, the limited follow-up data combined with the long-life expectancy in this generally young patient cohort and the possible selection and publication bias might distort these findings. Potentially higher long-term recurrence and hormone deficiency rates may even further tilt the scales in the risk–benefit assessment against the use of TSS. Before more conclusive and applicable recommendations for TSS in tGCT can be made, further research on oncological safety and functional outcome is necessary.

In our opinion, the current data (if at all) justify offering TSS only in well-informed patients with a singular testis, excellent compliance, a singular tumor less than 2 cm located at the lower pole of the testicle, and normal preoperative endocrine function. Unless patients plan to father a child within a short time frame, adjuvant testicular radiotherapy should be recommended after TSS.
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00345-022-04048-6.

Funding Open access funding provided by University of Zurich.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62:1006
2. Moher D, Shamseer L, Clarke M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4:1
3. Arda E, Cakiroglu B, Cetin G, Yuksel I (2007) Metachronous Testicular Cancer After Orchiectomy: A Rare Case. Cureus 9(11):e1833
4. Bojanic N, Bumbasirevic U, Bojanic G, Vukovic I, Milojevic B, Pekmezovic T (2017) Testis sparing surgery for treatment of small testicular lesions: is it feasible even in germ cell tumors? J Surg Oncol 115(3):287–290
5. Bojanic N, Bumbasirevic U, Vukovic I, Bojanic G, Milojevic B, Nale D et al (2014) Testis sparing surgery in the treatment of testicular germ cell tumors. Urology 84(4):S360
6. Ferretti L, Sargos P, Gross-Goupil M, Izard V, Wallerand H. Huyghe E et al (2014) Testicular-sparing surgery for bilateral or monorchide testicular tumours: a multicenter study of long-term oncological and functional results. BJU Int 114(6):860–864
7. Forbes CM, Metcalfe C, Murray N, Black PC (2013) Primary testicular tumours: Trials and tribulations of testicular preservation. Can Urol Assoc J 7(9–10):E630–3
8. Heidenreich A, Höltl W, Albrecht W, Pont J, Engelmann UH (1997) Testis-preserving surgery in bilateral testicular germ cell tumours. Br J Urol 79(2):253–7
9. Heidenreich A, Weissbach L, Höltl W et al (2001) Organ sparing surgery for malignant germ cell tumor of the testis. J Urol 166:2161
10. Keske M, Canda AE, Atmaca AF, Cakici OU, Arslan ME, Kamaci D et al (2019) Testis-sparing surgery: Experience in 13 patients with oncological and functional outcomes. Can Urol Assoc J 13(3):E83–E88
11. Kizilay F, Kalemci S, Şimşir A, Andabil HJ, Sarsik B, Şen S et al (2019) Long-term results of patients with testicular tumors undergoing testis sparing surgery: A single-center experience. J Urol Surg 6(2):93–99
12. Lawrentschuk N, Zuniga A, Grabowski AC, Rendon RA, Jewett MAS (2011) Partial orchiectomy for presumed malignancy in patients with a solitary testis due to a prior germ cell tumor: A large North American experience. J Urol 185(2):508–513
13. Nason GJ, Aditya I, Leao R et al (2020) Partial orchiectomy: The Princess Margaret cancer centre experience. Urol Oncol 38:605.e19
14. Sener TE, Ozveren B, Tinay I, Cam K, Turkeri L (2018) Clinical Case Discussion: Bilateral Synchronous Testicular Cancer and Organ-sparing Surgery. Eur Urol Focus 4(5):737–739
15. Steiner H, Höltl L, Maneschg C, Berger AP, Rogatsch H, Bartsch G et al (2003) Frozen section analysis-guided organ sparing approach in testicular tumors: Technique, feasibility, and long-term results. Urology 62(3):508–513
16. Xiao K, Wang X, Tan L, Qin Z, Zhou F, Ye Y (2018) Clinical analysis of 35 cases of benign testicular tumors. Chin J Clin Oncol 45(12):620–622
17. Morales-Barrera R, Valverde C, Rodon J, Perez J, Maldonado X, Suarez C et al (2010) Bilateral testicular germ cell tumours: a single hospital experience. Clin Transl Oncol 12(4):299–302
18. Weissbach L (1995) Organ preserving surgery of malignant germ cell tumors. J Urol 153(1):90–93
19. Benelli A, Varca V, Derchi L, Gregori A, Carmignani G, Simonato A (2017) Evaluation of the decision-making process in the conservative approach to small testicular masses. Urol J 84(2):83–87
20. De Stefani S, Isgro G, Varca V, Pecchi A, Bianchi G, Carmignani G et al (2012) Microsurgical testissparing surgery in small testicular masses: seven years retrospective management and results. Urology 79(4):858–862
21. Demir A, Onol FF, Eren F, Türkeri L (2004) Testis-sparing surgery in an adult with bilateral synchronous seminomatous tumor. Int J Urol 11(12):1142–1144
22. Heidenreich A, Bonfïg R, Derscham W, Von Vietsch H, Wilbert DM, Donohue JP et al (1995) Aconservative approach to bilateral testicular germ cell tumors. J Urol 153(1):10–13
23. Hughes PD (2006) Partial orchiectomy for malignancy with consideration of carcinoma in situ. ANZ J Surg 76(1–2):92–94
24. Kazem I, Danella JF (1999) Organ preservation for the treatment of contralateral testicular seminoma. Radiother Oncol 53(1):45–47
25. Kirkali Z, Tuzel E, Canda AE, Mungan MU (2001) Testis sparing surgery for the treatment of a sequential bilateral testicular germ cell tumor. Int J Urol 8(12):710–712
26. Lagabriele S, Durand X, Droupy S, Izard V, Marcelli F, Huyghe E et al (2018) Testicular tumours discovered during infertility workup are predominantly benign and could initially be managed by sparing surgery. J Surg Oncol 118(4):630–635
27. Leonhartshberger N, Pichler R, Stoehr B, Horninger W, Steiner H (2014) Organ preservation technique without ischemia in patients with testicular tumor. Urology 83(5):1107–11
28. Beyer J, Collette L, Daugaard G et al (2020) Prognostic factors in advanced seminoma: an analysis from the IGCCCG Update Consortium. J Clin Oncol 38:386
29. Stephenson A, Eggener SE, Bass EB et al (2019) Diagnosis and treatment of early stage testicular cancer: AUA guideline. J Urol 202:272
30. Giannarini G, Dieckmann KP, Albers P et al (2010) Organ-sparing surgery for adult testicular tumors: a systematic review of the literature. Eur Urol 57:780
31. Patel HD, Gupta M, Cheaib JG et al (2020) Testis-sparing surgery and scrotal violation for testicular masses suspicious for malignancy: a systematic review and meta-analysis. Urol Oncol 38:344
32. Ory J, Blankstein U, Gonzalez DC et al (2021) Outcomes of organ-sparing surgery for adult testicular tumors: a systematic review of the literature. BJUI Compass 2:306
33. Favilla V, Russo GI, Spitaleri F et al (2014) Multifocality in testicular germ cell tumor (TGCT): what is the significance of this finding? Int Urol Nephrol 46:1131
34. Dieckmann KP, Skakkebaek NE (1999) Carcinoma in situ of the testis: review of biological and clinical features. Int J Cancer 83:815
35. Hoei-Hansen CE, Rajpert-De Meyts E, Daugaard G et al (2005) Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review. Ann Oncol 16:863
36. Schrader M, Müller M, Sofikitis N et al (2003) “Onco-tese”: testicular sperm extraction in azoospermic cancer patients before chemotherapy-new guidelines? Urology 61:421
37. Kollmannsberger C, Tandstad T, Bedard PL et al (2015) Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol 33:51
38. Daugaard G, Gundgaard MG, Mortensen MS et al (2014) Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort. J Clin Oncol 32:3817
39. Sedlmayer F, Hoeltl W, Kozak W et al (2001) Radiotherapy of testicular intraepithelial neoplasia (TIN): a novel treatment regimen for a rare disease. Int J Radiat Oncol Biol Phys 50:909
40. Petersen PM, Giwercman A, Daugaard G et al (2002) Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis. J Clin Oncol 20:1537

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.